Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O95622
UPID:
ADCY5_HUMAN
Alternative names:
ATP pyrophosphate-lyase 5; Adenylate cyclase type V; Adenylyl cyclase 5
Alternative UPACC:
O95622; B7Z8A6; Q7RTV7; Q8NFM3
Background:
Adenylate cyclase type 5, also known as ATP pyrophosphate-lyase 5 or Adenylyl cyclase 5, plays a pivotal role in cellular signaling by catalyzing the formation of cAMP in response to G-protein signaling. This enzyme is integral in mediating signaling downstream of ADRB1, regulating cytosolic Ca(2+) levels, and contributing to Ca(2+)-dependent insulin secretion.
Therapeutic significance:
The protein is linked to two autosomal recessive disorders: Dyskinesia with orofacial involvement and Neurodevelopmental disorder with hyperkinetic movements and dyskinesia. These conditions underscore the protein's critical role in neurological development and function, presenting avenues for therapeutic intervention.